Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas

Virchows Archiv

Volumn 456, Issue 5, 2010, Pages 515-521

  Mete, Özgür ^a   Kapran, Yersu ^a   Güllüoglu, Mine G ^a   Kiliçaslan, Isin ^a   Erbil, Yesim ^a   Senyürek, Yasemin Giles ^a   Dizdaroglu, Ferhunde ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Adrenocortical adenoma; Adrenocortical carcinoma; CD10; Hepatocellular carcinoma; Renal cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; CANCER ANTIBODY; CD10 ANTIBODY; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; UNCLASSIFIED DRUG; MEMBRANE METALLOENDOPEPTIDASE; TUMOR ANTIGEN;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER MORPHOLOGY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; STAINING; TUMOR DIFFERENTIATION; ADRENAL CORTEX TUMOR; BIOSYNTHESIS; IMMUNOLOGY; KIDNEY TUMOR; LIVER TUMOR; MIDDLE AGED;

ADRENAL CORTEX NEOPLASMS; ADULT; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEPRILYSIN;

EID: 77952521772     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-0901-0     Document Type: Article

References (18)

1. McIntosh GG, Lodge AJ, Watson P et al (1999) NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffinembedded tissue. Am J Pathol 154:77-82
2. Chu P, Arber DA (2000) Paraffin-section detection of CD10 in 505 non-hematopoietic neoplasms: frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 113:373-382
3. Langner C, Ratschek M, Rehak P et al (2004) CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathol 45:460-467
4. Avery AK, Beckstead J, Renshaw AA et al (2000) Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 24:203-210
5. Pan CC, Chen PC, Tsay SH et al (2005) Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol 13:347-352
6. Mete O, Kilicaslan I, Uysal V (2009) Does CD10 immunoexpression have a diagnostic utility in the differential diagnosis of renal oncocytomas and eosinophilic variants of chromophobe renal cell carcinomas? Pathol 41:191-193
7. Pan CC, Chen PCH, Ho DMT (2004) The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathol 45:452-459
8. Kato I, Inayama Y, Yamanaka S et al (2009) Epithelioid angiomyolipoma of the kidney. Pathol Int 59:38-43
9. Papandreou CN, Nanus DM (2010) Is methylation the key to CD10 loss? J Pediatr Hematol Oncol 32:2-3
10. DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. IARC, Lyon
11. Stewart CJ, Nandini CL, Richmond JA (2000) Value of A103 (Melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. J Clin Pathol 53:206-211
12. Aydin H, Magi-Galluzzi C, Lane BR et al (2009) Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol 33:289-297
13. Zamecnik M, Michal M, Mukensnabl P (2003) Reactivity of granular cell tumors for inhibin and other markers of sex cord and steroid cell differentiation. Am J Surg Pathol 27:413-414
14. Schraith DF, Hahm GK, Niemann TH et al (2003) Alpha-inhibin immunoreactivity in soft-tissue neoplasia. Mod Pathol 16:1205-1209
15. Banerjee SS, Eyden B (2008) Divergent differentiation in malignant melanomas: a review. Histopathol 52:119-129
16. Doghman M, Cazareth J, Douguet D et al (2009) Inhibition of adrenocortical carcinoma cells proliferation by SF-1 inverse agonists. J Clin Endocrinol Metab 94:2178-2183
17. Bakke M, Zhao L, Hanley NA et al (2001) SF-1: a critical mediator of steroidogenesis. Mol Cell Endocrinol 171:5-7
18. Kaneko T, Kojima Y, Umemoto Y et al (2008) Usefulness of transcription factors Ad4BP/SF-1 and DAX-1 as immunohistologic markers for diagnosis of advanced adrenocortical carcinoma. Horm Res 70:294-299